Literature DB >> 17544369

Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides.

Ann T Poblenz1, Joerg J Jacoby, Sujay Singh, Bryant G Darnay.   

Abstract

RANK and RANKL are essential mediators of osteoclastogenesis. RANK interacts with members of the tumor necrosis factor receptor-associated factor (TRAF) family, of which TRAF6 is the critical signaling molecule. We identified a unique TRAF6-binding motif in RANK, which was subsequently co-crystallized with TRAF6 revealing distinct molecular interactions. A cell-permeable TRAF6 decoy peptide (T6DP) was shown to specifically target TRAF6 and inhibit RANKL-mediated signaling. In this study, we identified a core motif for binding to TRAF6 by generating a series of deletion mutants linked via palmitate as a means to internalize the peptide, thus making a smaller scaffold for intracellular delivery. The core motif of RKIPTEDEY inhibited RANKL-mediated osteoclastogenesis and bone resorption. In contrast, TRAF2/5 decoy peptides appeared to have no affect. Thus, disruption of the RANK-TRAF6 interaction may prove useful as a novel target for the development of a small molecule therapeutic agent for the treatment of bone-related diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544369     DOI: 10.1016/j.bbrc.2007.05.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review.

Authors:  Maximiliano Javier Jiménez-Dalmaroni; M Eric Gerswhin; Iannis E Adamopoulos
Journal:  Autoimmun Rev       Date:  2015-08-20       Impact factor: 9.754

Review 2.  TRAF6 activation in multiple myeloma: a potential therapeutic target.

Authors:  Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Haiming Chen; James Berenson; Benjamin Bonavida
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-03-21

3.  TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis.

Authors:  Betty Lamothe; YunJu Lai; Min Xie; Michael D Schneider; Bryant G Darnay
Journal:  Mol Cell Biol       Date:  2012-11-19       Impact factor: 4.272

4.  TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell.

Authors:  Qingbing Meng; Minqian Zheng; Hongbing Liu; Changzhi Song; Wensheng Zhang; Juan Yan; Ling Qin; Xiaolan Liu
Journal:  Mol Cell Biochem       Date:  2012-08-12       Impact factor: 3.396

5.  TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells.

Authors:  Xinfeng Wang; Jingjing Wang; Hong Liu; Ruirong Xu; Runsheng Ding; Shenhua Jiang; Xudong Wang; Hongming Huang
Journal:  Med Oncol       Date:  2015-09-03       Impact factor: 3.064

6.  The Simultaneous Inhibitory Effect of Niclosamide on RANKL-Induced Osteoclast Formation and Osteoblast Differentiation.

Authors:  Fei-Lan Liu; Chun-Liang Chen; Chia-Chung Lee; Cheng-Chi Wu; Teng-Hsu Hsu; Chang-Youh Tsai; Hsu-Shan Huang; Deh-Ming Chang
Journal:  Int J Med Sci       Date:  2017-07-19       Impact factor: 3.738

7.  TRAF6 mediates human DNA2 polyubiquitination and nuclear localization to maintain nuclear genome integrity.

Authors:  Yuan Meng; Changwei Liu; Lei Shen; Mian Zhou; Wenpeng Liu; Claudia Kowolik; Judith L Campbell; Li Zheng; Binghui Shen
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

8.  Ultrasonication Improves Solid Phase Synthesis of Peptides Specific for Fibroblast Growth Factor Receptor and for the Protein-Protein Interface RANK-TRAF6.

Authors:  Rúben D M Silva; João Franco Machado; Kyle Gonçalves; Francisco M Lucas; Salete Batista; Rita Melo; Tânia S Morais; João D G Correia
Journal:  Molecules       Date:  2021-12-03       Impact factor: 4.411

9.  Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis.

Authors:  Kenichi Mishima; Hiroshi Kitoh; Bisei Ohkawara; Tatsuya Okuno; Mikako Ito; Akio Masuda; Naoki Ishiguro; Kinji Ohno
Journal:  EBioMedicine       Date:  2015-11-17       Impact factor: 8.143

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.